Entyvio® is an ulcerative colitis drug that has been linked to reports of serious lung side effects, such as interstitial lung disease, shortness of breath, and even death.
Need a Texas Ulcerative Colitis Lawyer? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one was diagnosed with Interstitial Lung Disease after taking Entyvio for ulcerative colitis, you should contact our lawyers immediately. You may be entitled to compensation by filing a lawsuit.
What is Ulcerative Colitis?
Ulcerative colitis is an inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in your digestive tract. There is no cure for ulcerative colitis, but medications can reduce symptoms. Unfortunately, a new medication called Entyvio® (Vedolizumab) has been linked to reports of lung disease.
Symptoms of Ulcerative Colitis
The symptoms of ulcerative colitis usually develop over time, rather than suddenly, and may include:
- Diarrhea, often with blood or pus
- Abdominal pain and cramping
- Rectal pain
- Rectal bleeding — passing small amount of blood with stool
- Urgency to defecate
- Inability to defecate despite urgency
- Weight loss
- In children, failure to grow
What is Entyvio?
Entyvio® (vedolizumab) is a prescription intravenous (IV) medication for adults with moderate-to-severe ulcerative colitis and Crohn’s disease. Entyvio is made by Takeda Pharmaceuticals and it was approved in the U.S. in 2014.
What is the Problem?
Entyvio has been linked to a growing number of reports of patients who developed severe lung diseases and other side effects, including patients who died after suffering severe shortness of breath. Even so, the label on Entyvio fails to warn patients and doctors about the risk.
Symptoms of Lung Disease
Patients with ulcerative colitis who take Entyvio should seek medical attention if they have symptoms of lung disease, such as:
- Chest pain
- Shortness of breath
- Trouble breathing
- Persistent cough
- Unusual loss of appetite or unexplained weight-loss
- Low oxygen levels in the body
Entyvio Side Effects in the Lungs
- Interstitial lung disease
- Parenchymal lung disease
- Lung fibrosis (scarring)
- Pulmonary disease
- Respiratory failure
- And more
Case Reports of Lung Disease in Entyvio Patients
In January 2018, the American Journal of Gastroenterology published a case report of a 28-year-old patient who developed serious lung problems after 3 infusions of Entyvio. He suffered from shortness of breath, dry cough, fibrosis, and inflammation of the lungs.
In February 2021, the European Journal of Case Reports in Internal Medicine published a report of a person who developed granulomatous lung disease after being treated with Entyvio.
In December 2021, the European Journal of Gastroenterology published a case report of a 39-year-old man with ulcerative colitis who was diagnosed with a “severe interstitial lung injury.” He had to stop taking Entyvio and receive systemic anti-inflammatory steroids.
In February 2020, the journal Gastroenterology published a case report of a 52-year-old woman who developed shortness of breath, cough, and was diagnosed with parenchymal lung disease after receiving Entyvio.
In February 2022, the World Journal of Clinical Cases published a report of a man in China who died after 2 doses of Entyvio. He reportedly developed a severe interstitial lung disease with a persistent fever and worsening shortness of breath.
Need an Ulcerative Colitis Lawyer in Texas?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact our law firm for a free case review.